Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.46 |
| ▸ | CLK2 | P49760 | 7/20 | 0.46 |
| ▸ | TYK2 | P29597 | 4/20 | 0.46 |
| ▸ | JAK3 | P52333 | 4/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | PLK4 | O00444 | 3/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.46 |
| ▸ | DYRK3 | O43781 | 3/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | CDK1 | P06493 | 3/20 | 0.46 |
| ▸ | MARK3 | P27448 | 3/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.46 |
| ▸ | MARK2 | Q7KZI7 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25936215 | 0.89 | JAK2 (0.50) | JAK2DYRK1ACLK2TYK2JAK3 | |
| SCHEMBL24137915 | 0.88 | JAK2 (0.57) | JAK2DYRK1ACLK2TYK2JAK3 | |
| SCHEMBL24137538 | 0.81 | FDPS (0.50) | DYRK1ACLK2CDK2DYRK3ROCK2 | |
| SCHEMBL24137560 | 0.79 | CDK2 (0.57) | JAK2DYRK1AJAK3CDK2DAPK3 | |
| SCHEMBL22191810 | 0.79 | THRB (0.53) | DYRK1AAKT1 | |
| SCHEMBL24137727 | 0.77 | JAK2 (0.52) | JAK2DYRK1ACLK2TYK2JAK3 | |
| SCHEMBL24137537 | 0.75 | DHFR (0.41) | ROCK2DHFR | |
| SCHEMBL25935940 | 0.75 | GSK3B (0.46) | JAK2DYRK1ACLK2WNT1CLK3 | |
| SCHEMBL25933934 | 0.74 | CCNC (0.44) | JAK2DYRK1ACLK2CDK2DYRK3 | |
| SCHEMBL24137791 | 0.74 | GHSR (0.41) | MAP4K4DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-07-27 | — | — | US | disclosed |
| WO-2021263129-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234935-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | PACSIN2, MAP3K20, PHKG1 | JAK2 228/4885DYRK1A 495/4885CLK2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.